OREXIGEN THERAPEUTICS, INC. CONSULTING AGREEMENTConsulting Agreement • November 9th, 2015 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • California
THIS CONSULTING AGREEMENT (this “Agreement”) is effective as of October 1, 2015 (the “Effective Date”), by and between OREXIGEN THERAPEUTICS, INC. (the “Company”) and MARK BOOTH (the “Consultant”).
THIRD AMENDMENT TO LEASELease • November 9th, 2015 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO LEASE (“Third Amendment”) is made and entered into as of the 17th day of August, 2015, by and between MULLROCK 3 TORREY PINES, LLC, a Delaware limited liability company (“Landlord”) and OREXIGEN THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
AMENDED AND RESTATED COLLABORATION AGREEMENT BY AND BETWEEN OREXIGEN THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICAL COMPANY LIMITED DATED July 31, 2015Collaboration Agreement • November 9th, 2015 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
• The number of PDEs to be performed annually by the Parties shall be determined by the JCC and set forth in the Commercialization Plan, within the limitations and rights set forth in Sections 3.5.1 and 3.5.2 of this Agreement, taking into consideration prescribing levels, geographic territory, centers of excellence, target groups, detail position and other relevant considerations as the JCC may determine;
